Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
C6591 Taurochenodeoxycholic acid sodium salt -
B6172 PD-1/PD-L1 inhibitor 1Summary: PD-1/PD-L1 interaction inhibitor -
C3520 Arylquin 1Summary: potent secretagogue of the tumor suppressor protein prostate apoptosis response-4 (Par-4) -
B1931 Dimethyl FumarateSummary: nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator -
B3422 U-731221 CitationTarget: PC-PLCSummary: inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase) -
A1094 tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus]Summary: P53 binding protein fragment -
A4390 Pemetrexed1 CitationTarget: Thymidylate Synthase|DHFR|GARFTSummary: TS, DHFR,GARFT and AICARFT inhibitor -
A3118 3,3'-DiindolylmethaneSummary: Anticancer and antineoplastic agent -
A3196 AT-101Target: NS3/4a ProteasesSummary: BH3-mimetic,gossypol enantiomer -
A3541 LCL1619 CitationTarget: Inhibitor of apoptosis proteins (IAP)Summary: Antagonist of IAPs inhibitor

